InflaRx Announces GOHIBIC (Vilobelimab) Selected By BARDA For Phase 2 Study On Acute Respiratory Distress Syndrome; One Of Three Investigational Therapies Chosen By U.S. Department Of Health And Human Services
InflaRx Announces GOHIBIC (Vilobelimab) Selected By BARDA For Phase 2 Study On Acute Respiratory Distress Syndrome; One Of Three Investigational Therapies Chosen By U.S. Department Of Health And Human Services
InflaRx宣佈GOHIBIC (Vilobelimab)被BARDA選中，用於急性呼吸窘迫綜合症的第二階段研究；該療法是美國衛生及公衆服務部選定的三種研究性療法之一。
- DSMB Recommends Continuation without Modification for Third Time
- Safety Review Included 395 Patients
- Interim Survival Analysis Still Expected Early 2025 given Lower-Than-Expected Event Rate
- Low Event Rate Suggests Potential for Prolonged Survival
- Rapid Enrollment Positions Company for Enrollment Completion by Q1 2025; Earlier Than Expected
- DSMB建議第三次繼續進行，未作出修改。
- 安全性評估涉及395名患者。
- 預計2025年初進行中期生存分析，由於事件率低於預期。
- 事件率低說明存在延長生存期的潛力。
- 快速招募使公司能在2025年第一季度完成招募，比預期提前。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。